Tonix Pharmaceuticals Holding (TNXP) Net Cash Flow (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Net Cash Flow for 17 years, with the latest figure at -$9.3 million in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 46.18% year-over-year to -$9.3 million in Q2 2026; TTM through Jun 2026 was $50.5 million, a 58.36% decrease from a year earlier, with the FY2025 full-year figure at $110.2 million, up 49.21% from the prior year.
• Net Cash Flow was -$9.3 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from -$23.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $70.5 million in Q4 2024, with the low at -$48.2 million in Q1 2023.
• Average Net Cash Flow over 5 years is -$114277.8, with a median of -$7.9 million recorded in 2025.
• The largest YoY upside for Net Cash Flow was 2318.45% in 2022 against a maximum downside of 359.14% in 2022.
• Over 5 years, Net Cash Flow stood at -$19.7 million in 2022, then jumped by 190.88% to $17.9 million in 2023, then jumped by 293.03% to $70.5 million in 2024, then plunged by 73.81% to $18.5 million in 2025, then tumbled by 150.48% to -$9.3 million in 2026.
• The last three Net Cash Flow figures came in at -$9.3 million (Q2 2026), -$23.8 million (Q1 2026), and $18.5 million (Q4 2025), per Business Quant data.